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INTRODUCTION
Ectopic adrenocorticotropic hormone (ACTH)-secreting syndrome (EAS) is a relatively rare disease with an incidence of 1/million/year. [1] EAS is reported to be associated with many malignant tumors. [2] During recent years, several tumors such as small cell lung carcinoma (SCLC), neuroendocrine tumors, phaeochromocytomas, and medullary carcinoma of the thyroid have emerged as causes of EAS. [3, 4] Clinically, the presentations of EAS are similar to Cushing disease and poses a diagnostic challenge in localization of the ACTH source. The manifestations of EAS include hypertension, edema, hypokalemia, weakness and abnormal glucose tolerance, and so on. Biochemical testing showed obviously increase in plasma ACTH and cortisol level, which could not be inhibited by endogenous or exogenous glucocorticoid. [5] Glucocorticoids, a class of stress-induced steroid hormones synthesized by the adrenal cortex, which is strictly under the control of the hypothalamic-pituitaryadrenal axis. [6] Glucocorticoids in humans are known to regulate diverse cellular functions including development, homeostasis, metabolism, cognition, and inflammation. Endogenous glucocorticoid levels in the serum display a classic circadian pattern, peaking at the beginning of the period of the highest activity. High level of ectopic serum ACTH cannot be suppressed by endogenous or exogenous glucocorticoid, and this is the cardinal characteristic of EAS.
Glucocorticoids mediate their effect through intracellular glucocorticoid receptor (GR), which belongs to a large family of transcription factors known as the nuclear hormone receptors. It is well documented that the level of GR protein determines the magnitude of glucocorticoid response. Therefore, we aimed to explore the ACTH and GR expression in SCLC patients with or without EAS.
MATERIALS AND METHODS

Ethical statement
The study was approved by Ethics Committee of Beijing Luhe Hospital. We collected pulmonary tissue from healthy, non-EAS-SCLC, EAS-SCLC patients.
Immunohistochemistry
The slice was dewaxed by xylene and re-watered by alcohol. Three percent H 2 O 2 at room temperature for 10 min. The citric acid buffer was soaked at 100°C for 20 min. The first antibody was incubated in a refrigerator at 4°C overnight and washed by phosphate buffered solution (PBS) for 3 times. The second antibody was added dropwise, incubated at 37°C for 1 h, washed by PBS for 3 times, and 3, 3'-diaminobenzidine (DAB) developed color for 5 min. Hematoxylin was re-dyed for 2 min, then sealed and observed under the microscope.
Positive criteria
The semi-quantitative method was used, mainly according to the staining intensity, range, and number of positive cells. Weak positive: the number of positive cells is <30%; medium-strong positive: the number of positive cells is 30%-60%; and strong positive: the number of positive cells is more than 60%.
RESULTS
The case and laboratory examinations
A 70-year-old female visited her primary care for worsening fatigue with lower limbs for more than 20 days. The patient has a history of more than 60 years of heavy smoking, 10 cigarettes per day. Laboratory testing as an outpatient revealed hypokalemia of 2.15 mmol/L (3.5-5.5 mmol/L). In addition, the patient showed increased blood pressure, blood glucose level, and hypoproteinemia. There was no history of diabetes mellitus or hypertension. The patient was then admitted to the hospital. The vitals were heart rate of 74 bpm, blood pressure of 144/66 mmHg, and respiratory rate of 18 bpm. Physical examination showed edema in the lower limbs; the rest of examination was within normal limits.
After admission, her hypokalemia was refractory, although continuous oral and intravenous potassium supplements. Table 1 .
Adrenocorticotropic hormone and glucocorticoid receptor expression in SCLC patients with or without ectopic adrenocorticotropic hormone syndrome
High-dose dexamethasone suppression test is well known to be an important test in the diagnosis of ectopic ACTH syndrome. We examined the ACTH and GR expression in SCLC patients with or without EAS. The pituitary gland tissue was also stained with ACTH and GR antibodies as a positive control. There was no difference in the ACTH and GR expression between control and SCLC patients without EAS [ Figure 1 ]. Compared with control, ACTH expression obviously increased while GR expression reduced in the SCLC patient with EAS [ Figure 2 ], suggesting the reduction of GR expression may contribute to the no inhibition of high-dose dexamethasone.
DISCUSSION
The anti-inflammatory and immunosuppressive effects of glucocorticoids are exploited extensively. Endogenous glucocorticoids are stress-induced hormones synthesized under the control of the hypothalamic-pituitary-adrenal axis. A high level of glucocorticoid could inhibit the secretion of ACTH, which is named as feedback. While the regulation is out of control in EAS, high-dose dexamethasone suppression test has been applied in the diagnosis of EAS based on the characteristic. However, the underlying mechanism is not clear. Multiple mechanisms have been proposed to explain the phenomenon. Reduced GR expression is thought to be an important factor in mediating glucocorticoid resistance.
The GR is a ubiquitously expressed protein, found in almost all human cell types and tissues at appreciable levels. It is well-established that the level of GR expression is closely correlated with the magnitude of the glucocorticoid response. [7] Therefore, GR expression level may be an important determinant of the glucocorticoid response. [8] Several studies have shown that reduced GR expression in primary acute lymphoblastic leukemia cells is associated with initial resistance to glucocorticoid therapy, relapse, and poor prognosis. [9, 10] In such cell lines, including SLC cell lines, reduced GR expression was reported. [8, 11] In our study, we collected pulmonary tissue from healthy, SCLC patients with or without EAS. Meanwhile, we collected tissue from pituitarium as a positive control. Immunochemistry analysis showed that there is no obvious difference in the expression of GR in SCLC patients without EAS compared with control group. While in SCLC patients with EAS, no obvious GR expression was seen in the pulmonary tissue. The results indicate that reduced GR expression may explain the no response to high-dose dexamethasone suppression test.
Several studies explored the mechanism of GR downregulation in cell lines. It is reported that glucocorticoid-induced downregulation of GR mRNA has been attributed to reduce transcription of the GR gene as well as decreased stability of the GR mRNA. [12, 13] While no data available of GR expression of pulmonary tissue in the SCLC patient with EAS. Suggesting the reduction of GR expression may contribute to the no inhibition of high-dose dexamethasone. More samples are still needed to confirm the phenomenon, and further studies are needed to illuminate the mechanism of GR downregulation or absent.
CONCLUSIONS
In SCLC patients with EAS, the reduction of GR expression may contribute to the no inhibition of high-dose dexamethasone.
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